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DOI 10.1186/s12974-015-0328-2RESEARCH Open AccessActivation of the kynurenine pathway and
increased production of the excitotoxin
quinolinic acid following traumatic brain
injury in humans
Edwin B. Yan1*†, Tony Frugier2†, Chai K. Lim3†, Benjamin Heng3†, Gayathri Sundaram4†, May Tan5†, Jeffrey V. Rosenfeld6,7,
David W. Walker8, Gilles J. Guillemin3 and Maria Cristina Morganti-Kossmann9,10Abstract: During inflammation, the kynurenine pathway (KP) metabolises the essential amino acid tryptophan (TRP)
potentially contributing to excitotoxicity via the release of quinolinic acid (QUIN) and 3-hydroxykynurenine (3HK).
Despite the importance of excitotoxicity in the development of secondary brain damage, investigations on the KP
in TBI are scarce. In this study, we comprehensively characterised changes in KP activation by measuring numerous
metabolites in cerebrospinal fluid (CSF) from TBI patients and assessing the expression of key KP enzymes in brain
tissue from TBI victims. Acute QUIN levels were further correlated with outcome scores to explore its prognostic
value in TBI recovery.
Methods: Twenty-eight patients with severe TBI (GCS ≤ 8, three patients had initial GCS = 9–10, but rapidly deteriorated
to ≤8) were recruited. CSF was collected from admission to day 5 post-injury. TRP, kynurenine (KYN), kynurenic
acid (KYNA), QUIN, anthranilic acid (AA) and 3-hydroxyanthranilic acid (3HAA) were measured in CSF. The Glasgow
Outcome Scale Extended (GOSE) score was assessed at 6 months post-TBI. Post-mortem brains were obtained
from the Australian Neurotrauma Tissue and Fluid Bank and used in qPCR for quantitating expression of KP enzymes
(indoleamine 2,3-dioxygenase-1 (IDO1), kynurenase (KYNase), kynurenine amino transferase-II (KAT-II), kynurenine
3-monooxygenase (KMO), 3-hydroxyanthranilic acid oxygenase (3HAO) and quinolinic acid phosphoribosyl transferase
(QPRTase) and IDO1 immunohistochemistry.
Results: In CSF, KYN, KYNA and QUIN were elevated whereas TRP, AA and 3HAA remained unchanged. The ratios of
QUIN:KYN, QUIN:KYNA, KYNA:KYN and 3HAA:AA revealed that QUIN levels were significantly higher than KYN and KYNA,
supporting increased neurotoxicity. Amplified IDO1 and KYNase mRNA expression was demonstrated on post-mortem
brains, and enhanced IDO1 protein coincided with overt tissue damage. QUIN levels in CSF were significantly higher
in patients with unfavourable outcome and inversely correlated with GOSE scores.
Conclusion: TBI induced a striking activation of the KP pathway with sustained increase of QUIN. The exceeding
production of QUIN together with increased IDO1 activation and mRNA expression in brain-injured areas suggests that
TBI selectively induces a robust stimulation of the neurotoxic branch of the KP pathway. QUIN’s detrimental roles are
supported by its association to adverse outcome potentially becoming an early prognostic factor post-TBI.
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Traumatic brain injury (TBI) is one of the leading causes of
morbidity and mortality in healthy individuals. Epidemio-
logic studies reported that TBI occurs more frequently in
young adults due to motor vehicle accidents, sport activities
and assaults as major causes of injury. Although advanced
progress in pre-hospital intervention, neuroimaging,
emergency management and intensive care as well as
neurosurgical techniques have reduced mortality after se-
vere TBI, the overall outcome remains poor with patients
suffering from long-term disability and mental illness.
TBI is distinguished in two phases, namely primary
and secondary injury. Primary injury occurs at the time of
trauma resulting from either direct physical impact (focal
trauma) or inertial force induced by rapid acceleration-
deceleration (diffuse trauma) or a combination of both
[1]. Subsequently, long-lasting secondary injury processes
commence lasting for minutes, hours and days following a
TBI. The combination of such pathological changes in the
brain’s intrinsic physiology and biochemistry aggravates
brain damage and possibly underlies the causes of death.
Over the past decades, compelling evidence has shown
that such delayed processes represent the most destructive
phase of TBI; however, the complexity and the mechanisms
of secondary brain injury require further elucidation.
There are few well-defined secondary pathways including
inflammation, oxidative stress and excitotoxicity that ter-
minate with the release of neurotoxins, leading to delayed
cell death.
The study presented in this paper aimed to investigate
changes in cerebral activation of the kynurenine pathway
(KP) induced by severe TBI, with a specific focus on the
potential roles of the terminal end product of the KP,
the neurotoxin quinolinic acid (QUIN) [2] in predicting
patients’ long-term outcome.
The KP is the major cascade for metabolism of the es-
sential amino acid tryptophan (TRP). TRP is the only
amino acid bound to albumin to form a TRP-albumin
complex in the blood stream [3]. This complex serves as
a buffering system for maintaining a relative constant
level of free TRP in blood. Free circulating TRP can be
transported across the blood-brain barrier into the brain
by the sodium-independent amino acid transporter system
[4]. TRP is required for the synthesis of all proteins to
ensure cell survival in both the periphery and central
nervous system. It also strongly influences the function
of the immune system in that reduction in TRP con-
centration suppresses the proliferation of peripheral
mononuclear cells [5], decreases the activation of allogenic
immune cells [6] and enhances the inhibition of T-cell
responses [7]. In this regard, in vivo studies have shown
that blocking the activity of the TRP-metabolising enzyme,
indoleamine 2,3-dioxygenase-1 (IDO1), in the brain re-
sults in maintenance of the TRP pool and consequentlythe proliferation of T cells [8]. In the brain, TRP is meta-
bolised to kynurenine (KYN) by IDO1 in neurons, as-
trocytes, microglia and infiltrated macrophages. KYN is
then further metabolised into other neuroactive products
of the KP such as kynurenic acid (KYNA), anthranilic acid
(AA), 3-hydroxykynurenine (3HK), 3-hydroxyanthranilic
acid (3HAA), QUIN, picolinic acid (PA) and nicotinic acid
(NA) [9].
Numerous metabolites of the KP have received consider-
able attention since they display neuroactive, neurotoxic or
immunomodulatory properties [10]. In fact, while QUIN
acts as an excitotoxic agonist to the N-methyl-D-aspartate
(NMDA) receptor, KYNA is rather considered a neuropro-
tectant through its antagonising action to the NMDA
receptor, thus having an opposite functional role to its
counterparts [11].
Therefore, understanding the changes in this complex
pathway that are triggered in pathological conditions is
critical for the future development of therapies to reduce
secondary brain tissue damage. These KP metabolites
are implicated in a variety of neuroinflammatory disorders
including Alzheimer’s disease, amyotrophic lateral sclerosis
(ALS) and the AIDS-dementia complex [9, 12–16]. With
the pathogenesis of neurological diseases, QUIN is likely
one of the most important end products of the KP (review
by [17]). In the primate and human brain, QUIN levels are
strongly induced by interferon gamma (IFN-γ), a cytokine
that is upregulated during infection and inflammation
[12, 18] and following hypoxia-ischemia [19]. QUIN
displays the ability to bind and activate the NMDA recep-
tor causing prolonged Ca2+ influx, with loss of intra- and
extra-cellular ionic balance in neurons; it increases cell
membrane permeability, contributes to vasogenic oedema
and ultimately leads to cell death [17].
Animal experiments employing intrastriatal injection
of QUIN resulted in substantial neuronal cell loss [20,
21], whereas peripheral QUIN administration increased
cerebral astrogliosis and oxidative stress [22]. Delivery of
QUIN into the brain produced a progressive mitochondrial
dysfunction, impaired cellular energy homeostasis [23, 24],
increased oxidative stress [25] and enhanced nitric oxide
(NO) synthase activities [26]. Even a modest (~200 nM)
but prolonged elevation of QUIN in the adult brain is
sufficient to reduce dendritic varicosities and microtubular
assemblies of human neurons in vitro [27].
Despite the relevance of QUIN production in the
pathogenesis of many neurological conditions, there are
only limited studies that reported changes in the levels of
QUIN and no reports at all in the TBI setting demonstrat-
ing changes of other metabolites of the KP. Published data
showed that increased concentration of QUIN in cerebro-
spinal fluid (CSF) is strongly associated with mortality in
children and adults after TBI [28, 29]. However, these early
reports have not assessed how elevated QUIN production
Table 1 Demographic information of TBI patients
Variables Values




Type of accident, n (%)





GCS, median (range) 5.5 (3–10)
GCS ≤ 8, n (%) 25 (89.3)
ISS, median (range) 36.5 (13–57)
GOSE, median (range) 4 (1–8)










A total of 28 patients with severe TBI were recruited in the study for longitudinal
collection of CSF and serum. The following clinical parameters were recorded:
Glasgow Coma Scale (GCS): severe ≤8. Injury Severity Score (ISS): 0 = no
injury, 75 = maximal untreatable injury. Glasgow Outcome Scale Extended
(GOSE): 1 = dead, 2 = vegetative state, 3 = lower severe disability, 4 = upper
severe disability, 5 = lower moderate disability, 6 = upper moderate disability,
7 = lower good recovery, 8 = upper good recovery
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intrinsic branches potentially leading to opposite, neu-
roprotective or neurotoxic sequel. Therefore, further
understanding of the activation of the KP consequent
to TBI is pivotal to pinpoint its roles in the progress of
secondary brain damage and develop a pharmacological
intervention targeting the specific step of this complex
pathway responsible for excessive QUIN synthesis [30].
In this study, we embarked on a comprehensive char-
acterisation of the KP by measuring six metabolites in
CSF collected from patients with severe TBI. In order to
elucidate the relationship between these metabolites and
the activation state of the KP, the level of expression of
six enzymes of the KP was examined using post-mortem
brain tissue obtained from individuals who died of TBI.
This study design hinges on the hypothesis that TBI
activates cerebral KP, enhances the production of neuro-
toxin QUIN and increases mRNA expression of enzymes
regulating QUIN production in the brain. We further
hypothesised that QUIN concentrations in CSF are
correlative with Glasgow Outcome Scale Extended (GOSE)
scores assessed at 6 months following TBI. Therefore,
measuring QUIN in the clinic may aid in assessing
long-term outcomes in severe TBI patients.
Materials and methods
Patient recruitment and CSF and serum sample collection
The study was conducted in accordance with the National
Statement on Ethical Conduct in Research Involving
Humans of the National Health and Medical Research
Council of Australia and was approved by the Human
Ethics Committee of the Alfred Hospital, Melbourne,
Australia. Twenty-eight severe TBI patients were recruited
from the Trauma Service of the Alfred Hospital (Table 1).
Formal consent was obtained from the next of kin before
the commencement of the study. The patient’s inclusion
criteria included severe TBI, established by a post-
resuscitation, pre-intubation Glasgow Coma Scale
(GCS) ≤ 8 (three patients had initial GCS = 9–10 but
rapidly deteriorated requiring intubation at the scene)
and implantation of an extraventricular drain (EVD)
for monitoring and decreasing intracranial pressure
via drainage of CSF. Exclusion criteria included age
below 18 years, pregnancy, history of neurodegenerative
disease, infectious disease, previous TBI and cancer.
Management of TBI patients included preliminary CT
scans within 4 h of admission to assess the extent of in-
jury and surgical implantation of an in situ intracranial
pressure (ICP) probe coupled with an EVD. CSF was
drained when the ICP was greater than 20 mmHg and
accumulated in a drainage bag over 24 h. The CSF was
collected daily by ICU research staff for six consecutive
days from admission to the hospital (day 0) until day 5
post-TBI. CSF was centrifuged at 2000×g for 15 min at4 °C, and the supernatant was stored at −80 °C until
analysis. Blood samples were also collected daily and
centrifuged, and serum was stored at −80 °C.
Assessment of outcomes
The outcome was assessed using the Glasgow Outcome
Scale Extended (GOSE) at 6 months post-injury. Phone
interviews with individual patients, their family members
or other informants were conducted by experienced re-
search nurses using the questionnaire of Wilson et al.
[31]. The GOSE is an examiner-dependent assessment;
therefore, research staffs conducting the interviews are
extensively trained to produce high-level consistency
among patients. GOSE aims to gauge the patient’s social,
occupational, behavioural and neurological recovery after
TBI, where GOSE 1 = death, 2 = vegetative state, 3 = se-
vere disability (lower band), 4 = severe disability (upper
band), 5 = moderate disability (lower band), 6 = moderate
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and 8 = good recovery (upper band).
Control patients and sample collection
Control CSF was obtained from patients undergoing
elective neurosurgery for implantation of ventriculo-
peritoneal shunts following a diagnosis of hydrocephalus
(n = 11, 6 males and 5 females, between the ages of 30
and 74 years). Ethics approval was granted by the Alfred
Human Ethics Board and informed consent was obtained
prior surgery. Exclusion criteria included involvement of
neurodegenerative diseases, cancer, infectious disease, in-
tracerebral haemorrhages or previous TBI. Control serum
samples (n = 20) were obtained from 12 female and 8 male
healthy volunteers between the ages of 21 and 55 years.
Both serum and CSF samples were processed using the
same methods as described for TBI patients.
Measurement of tryptophan metabolites in CSF and serum
CSF samples were analysed by high-performance liquid
chromatography (HPLC) and gas chromatography-mass
spectrometry (GC-MS) methods to quantify the con-
centration of the metabolites of the KP, namely TRP,
KYN, KYNA, AA, 3HAA and QUIN. TRP was only
measured in serum. Proteins in CSF and serum were
first precipitated by adding equal amount of 5 %
trichloroacetic acid (w/v, Sigma-Aldrich, St. Louis,
MO, USA) to the sample and then centrifuged for 10
min at 2000×g at 4 °C. The supernatants were filtered
through 0.2-μm filters (Waters, Rydalmer, NSW, Australia)
before use in HPLC.
The HPLC methods for quantification of TRP, KYN,
KYNA, AA and 3HAA were based on Darlington et al.
[32] with slight modification. The mobile phase of the
TRP, KYN and KYNA assay consisted of 50 mM sodium
acetate (Merck, Whitehouse Station, NJ, USA), 250 mM
zinc acetate (Sigma-Aldrich, St. Louis, MO, USA) and
5 % acetonitrile (Merck, Whitehouse Station, NJ, USA).
The mobile phase was buffered to pH 5.5 by glacial acet-
ate acid (Merck, Whitehouse Station, NJ, USA), filtered
through a 0.45-μm filter and pumped at a flow rate of
1 ml/min. The mobile phase of AA and 3HAA consisted
of 25 mM sodium acetate and 2.5 % acetonitrile, buff-
ered at pH 5.5, filtered and pumped at a flow rate of
1 ml/min. Stock standards of TRP, KYN, KYNA, AA
and 3HAA were made in concentration of 250 mM
using high-purity chemical from Sigma-Aldrich (St. Louis,
MO, USA). The stock standard solution was kept at 4 °C
for 1 month. Working standards were made by further di-
lution of the stock solution to establish standard curves of
1.25, 2.5, 6.25 and 12.5 μM for TRP and KYN; 10, 20, 60,
120 and 200 nM for KYNA; and 5, 15, 30 and 50 pM for
AA and 3HAA. Quality control samples were prepared
for each metabolite, aliquoted in multiple vials andstored at −80 °C. Deproteinised human CSF and serum
samples (100 μl), standards and quality controls were
injected into HPLC. The retention time and peak height of
each metabolite from each sample were quantified
using either WinChrom Chromatography Data System
(GBC, Melbourne, Australia) or Waters Millennium
Chromatography Manager (Waters, Rydalmer, NSW,
Australia). TRP, KYN and KYNA were separated using
a polymeric column (20 × 3.2 mm; 5-μm particle size;
Agilent Technologies, Forest Hill, VIC, Australia) and
detected by an absorbance detector for TRP and KYN
(Photodiode Array Detector, Shimadzu SPD-M10A
(Kyoto, Japan); absorbance wavelength TRP = 278 nm;
KYN = 363 nm) or a fluorescent detector for KYNA
(Waters 474 Scanning Fluorescence Detector, excitation =
344 nm, emission = 388 nm) connected in series. AA and
3HAA were measured by a Synergi Hydro column (250 ×
4.60 mm; 4 μm particle size; Phenomenex (Torrance, CA,
USA)) connected to a fluorescent detector (Waters
474 Scanning Fluorescence Detector, Ex = 320 nm,
Em = 420 nm). For each set of sample measurement,
fresh working standards were prepared and measured
together with unknown samples and quality controls.
A standard curve was plotted using linear regression
of the area under the chromatograph of the corresponding
concentration of the standards. The concentrations of
TRP, KYN, KYNA, AA and 3HAA were calculated against
the standard curves from the corresponding run of the
assay. Quality controls were used to calculate inter-
and intra-assay coefficient.
QUIN in CSF was measured by GC-MS as described
by Smythe et al. [33]. Briefly, a standard curve of QUIN
(10, 20, 50, 100, 200 and 500 nM) was prepared from a
stock solution (2 μM). An internal standard containing
50–200 fmol of [2H3]-QUIN in 50 μl was added into
100-μl deproteinised samples. These samples were then
dried by N2 stream. The residues were mixed with tri-
fluoroacetic anhydride (100 μl, Sigma-Aldrich, St. Louis,
MO, USA) and hexafluoroisopropanol (100 μl; Sigma-
Aldrich, St. Louis, MO, USA) and left at room temperature
overnight to produce the dihexafluoroisopropyl ester from
QUIN. The dihexafluoroisopropyl ester product was
dissolved in toluene (1 ml, Sigma-Aldrich, St. Louis,
MO, USA), washed with 5 % NaHCO3 (1 ml; Sigma-
Aldrich, St. Louis, MO, USA) and ddH2O (1 ml) and
dried over anhydrous sodium sulphate (~500 mg;
Sigma-Aldrich, St. Louis, MO, USA). The samples were
then transferred into an auto-sampler (7683, Agilent
Technologies, Forest Hill, VIC, Australia), and 1 μl was
injected into a HP-5MS capillary column (30 m × 0.25
mm; Agilent Technologies, Forest Hill, VIC, Australia)
connected to an Agilent 6890 gas chromatograph and
an Agilent mass selective detector (Agilent Technologies,
Forest Hill, VIC, Australia).
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All procedures were conducted in accordance with the
Australian National Health & Medical Research Coun-
cil’s National Statement on Ethical Conduct in Human
Research (2007), the Victorian Human Tissue Act
1982, the National Code of Ethical Autopsy Practice
and the Victorian Government Policies and Practices
in Relation to Post-Mortem.
Trauma brain samples from 16 individuals who died
after closed head injury were obtained from the Australian
Neurotrauma Tissue and Fluid Bank. Cases were aged
between 18 and 78 years (mean 49.9 years), and the
causes of injury include motor vehicle accident, motorbike
accident, nursing home accident, household accident, stair
accident and falls (see Table 2 for clinical information and
epidemiological details). The post-mortem intervals varied
between 40 and 129 h (mean 80.6 h).Table 2 Details of the 16 trauma and 10 control cases
Case Age (years) Sex Cause of injury
1 51.1 M Motor vehicle accident
2 78.7 M Nursing home accident
3 27 M Suicide
4 18.3 M Motor vehicle accident
5 57.9 F Motor vehicle accident
6 49 M Motor vehicle accident
7 34.7 M Motorbike accident
8 21.5 M Motor vehicle accident
9 57.6 F Motor vehicle accident
10 46.0 M Fall
11 56.3 M Motor vehicle accident
12 64.6 M Fall
13 75.9 M Staircase fall
14 59.6 F Motor vehicle accident
15 61.7 M Fall
16 38.9 F Staircase fall
17 16 M -
18 48.7 M -
19 51.6 M -
20 52.3 M -
21 59.6 M -
22 64.1 M -
23 66.9 M -
24 64.4 M -
25 77.5 M -
26 60 F -
Cases 1–9: cases with a survival time between 0 and 17 min; cases 10–16: cases wit
were obtained at autopsy
PMI post-mortem interval (time between death and brain retrieval), M male, F femaTissues were divided into four groups—Control, Acute
Death, Delayed Death Injured Tissue and Delayed Death
Normal Tissue. The Acute Death group includes nine
patients (seven males and two females) who were pro-
nounced dead upon the arrival of paramedics at the scene
of accident (survival time <17 min). In those victims with
an absence of visible tissue damage at post-mortem, cortical
tissue was collected directly under the area having marked
injury to the skull and skin. The group of delayed death
includes seven patients (five males and two females)
who survived more than 6 h post-TBI (range of 6–122 h,
mean survival time of 40 h). At autopsy, two full coronal
brain slices were taken by a forensic pathologist at 1 cm
posterior to the mammillary bodies at the level of the basal
ganglia. One slice was fresh frozen for PCR experiments,
and the other was fixed in formalin for immunohisto-
chemistry. The tissue used in these experiments was takenPMI (h) Cause of death Survival time
60 Brain + multiple injuries <17 min
45 Brain injury <17 min
84 Brain + multiple injuries <17 min
79 Brain + multiple injuries <17 min
87 Brain + multiple injuries <17 min
107 Brain + multiple injuries <17 min
66 Brain + multiple injuries <17 min
100 Brain injury <17 min
97 Brain injury <17 min
129 Brain injury 6 h
65 Brain injury 8 h
61 Brain injury 8 h
89 Brain injury 10 h
80 Brain injury 35 h
40 Brain injury 93 h
101 Brain injury 122 h
- Suicide by hanging -
50 Cardiac failure -
64 Asthma -
52 Cardiomyopathy -
43 Pulmonary embolism -
24 Ischaemic heart disease -
10 Pneumonia -
24 Pulmonary embolism -
53 Myocardial infarction -
48 Myocardial infarction -
h a survival time between 6 and 261 h; cases 17–26: control cases. All brains
le
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showing visible tissue damage (Delayed Death Injured Tis-
sue) and from a corresponding region on the contralateral
side of the brain without macroscopic injury (Delayed
Death Normal Tissue). These groupings were consistent
with our previous reports [34–36].
For comparison, the same regions analysed in TBI tissues
were obtained from control brain samples. These were
provided by the National Neural Tissue Resource Centre of
Australia (n = 13). These brains originated from individuals
with no history of TBI or neuropathology; the age range
matched that of TBI population and was between 16
and 78 years old (mean 58 years old). A neuropathologist,
Prof. C. McLean, Head of the Department of Anatomical
Pathology at the Alfred Hospital, performed brain tissue
pathology and injury identification.
Gene expression of enzymes regulating the kynurenine
pathway
The RNA isolation and cDNA preparation was performed
using a well-characterised methodology as described previ-
ously in these brains by our group [36]. Briefly, TRIzol Plus
RNA purification kit was used for RNA extraction from
fresh frozen cortex tissue. A Nanodrop1000 spectropho-
tometer (Thermo Fisher Scientific, Wilmington, DE, USA)
was used to determine the concentration and purity of the
RNA samples. A minimum ratio of absorbance at 260 and
280 nm of 2 was considered as pure RNA. Agilent 2100
bioanalyzer (Agilent Technologies, Waldbronn, Germany)
was used to assess the integrity of extracted RNA. RNA
quality is considered good if the sample has a minimum
RNA integrity number (RIN) value of 6. Oligo d(T)20 was
then used as primers to reverse transcribed RNA fraction
into cDNA using SuperScript III reverse transcriptase
according to the manufacturer’s protocol (Invitrogen,
Carlsbad, CA, USA). Quantitative PCR was performed
using TaqMan primer for kynurenase (KYNase, Hs00187
560_m1), kynurenine amino transferase-II (KAT-II, Hs0021
2039_m1), kynurenine 3-monooxygenase (KMO, Hs00175
738_m1), 3-hydroxyanthranilic acid oxygenase (3HAO, Hs
00201915_m1) and quinolinic acid phosphoribosyl
transferase (QPRTase, Hs00204757_m1) (Applied Biosys-
tems, Foster City, CA, USA). Hydroxymethylbilane syn-
thase (HMBS, Hs00609297_m1), peptidylpropyl isomerase
A (cyclophilin A) (PPIA, Hs99999904_m1), ubiquitin C
(UBC, Hs00824723_m1) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, Hs99999905_m1) (Applied
Biosystems, Foster City, CA, USA) have the most stable
mRNA levels in post-mortem brain tissue and were used
as endogenous control.
Quantitative PCR (qPCR) reaction mixture for each
sample contains 1 μl of cDNA, 12.5 μl Taq-Man Universal
PCR Master Mix (Applied Biosystems, Foster City, CA,
USA), 1.25 μl of primer and 10.25 μl nuclease-free H2O.Seven microlitres of the reaction mixture was added into a
384 well plate, and qPCRs were performed using the
7900HT Fast Real-Time PCR system (Applied Biosystems,
Foster City, CA, USA). All experiments were performed in
triplicate. The level of mRNA expression of KP enzymes
was quantified using the comparative Ct method (ΔΔCt).
This method used an arithmetic formula (2−ΔΔCt) instead
of a standard curve for the calculation of the relative KP
enzyme expression level. This method can be used in
place of the standard curve as long as both target and
housekeeping genes have been validated to have approxi-
mate equal efficiencies. The mRNA levels of KP enzymes
were normalised using the averaged level of endogenous
control gene (HMBS, PPIA, UBC and GAPDH).
For IDO1, the primer forward (GCCAGCTTCGAGAA
AGAGTTG) and reverse (TGACTTGTGGTCTGTGAG
ATGA) were made based on Harvard primer bank (http://
pga.mgh.harvard.edu/primerbank/, assessed on April 2012).
qPCR reactions were performed in a final volume of 10 μl.
Each reaction mixture contains 5 μl Fast SYBR® green
master mix, 5 μM forward and reverse primers and 125
ng of cDNA template. The reaction was incubated at
95 °C for 20 s and amplified for 40 cycles of 95 °C for 1 s
and 55 °C for 20 s.
IDO1 immunohistochemistry
Localisation and distribution of cells expressing IDO1 were
identified using immunohistochemical staining. Cortical
tissues were immersion fixed in 4 % paraformaldehyde
for 72 h before paraffin-embedding process. Immuno-
histochemistry was performed on 7-μm sections using
a Dako Autostainer XL (DakoCytomation, Carpinteria,
CA, USA). In brief, sections were deparaffinised and
rehydrated and then subjected to antigen retrieval in a
citrate buffer (Dako (Cambridge, UK), S2367, pH 9) within
a pressurised heating chamber (Dako (Cambridge, UK),
S2800, 125 °C, 20 psi) for 2 min. Quenching of endogenous
peroxidase activity was achieved using 3 % H2O2. Sections
were then treated with serum-free protein blocker (Dako
(Cambridge, UK), X0909) before 120-min incubation with
antibody against IDO1 (IDO-MCA, 1:100, Oriental Yeast
Co., Ltd., Tokyo, Japan). Envision HRP-linked polymer
(Dako (Cambridge, UK), K4001) and 3,3-diaminobenzidine
(Dako (Cambridge, UK), K3468) were applied to visualise
positive staining. Tissue sections were counterstained with
haematoxylin on a Leica Autostainer XL (North Ryde,
NSW, Australia) and coverslipped using a Leica CV5030
device (North Ryde, NSW, Australia). Isotype-matched
monoclonal antibody was used as a negative control. All
sections were examined under a light microscope (Leica
DM2500, North Ryde, NSW, Australia) and positive-
stained cells were counted semi-quantitatively by ImageJ
software as number of positive cell × 100/total number
of cells in ten random microscopic (×200) fields in each
Yan et al. Journal of Neuroinflammation  (2015) 12:110 Page 7 of 17section. Statistical analyses were performed using
GraphPad Prism Version 6 software (mean ± SE). All
tests were two-tailed with 95 % confidence interval
values (p < 0.05).
Statistical analysis
Tryptophan metabolites
Statistical analyses were undertaken using GraphPad
Prism 5. Generally, for all data sets, we first tested the
data for homogeneity of variance using Bartlett’s test
prior to applying further analysis. Due to non-normally
distributed metabolite data, logarithmic transformation
was applied before analysis using one-way ANOVA and
Dunnett post hoc for multiple comparisons between con-
trol group and each day after TBI. Differences in QUIN
levels in CSF between favourable (GOSE 5–8) and un-
favourable outcome (GOSE 1–4) was determined by
Student’s t-test following logarithmic transformation.
To reflect logarithmic transformation of data, results
were presented as geometric means with 95 % confi-
dence intervals throughout. Correlation between QUIN
and GOSE was conducted using Spearman’s correlation
coefficient. A p value of less than 0.05 was considered
as statistically significant.
qPCR
Statistical analyses were undertaken using GraphPad
Prism 5. Due to non-normally distributed data; logarithmic
transformation was applied before analysed using 1-way
ANOVA and Dunnett post hoc for multiple comparisons
between each group. A p value of less than 0.05 was consid-
ered as statistically significant.
Results
Patient demographics and outcome
A total of 28 TBI patients were recruited immediately
after resuscitation at the accident scene and admitted to
the ICU. TBI patients’ age ranged between 21 and 69
years (median age of 35 years) with a majority of males
(n = 22, 62.9 %) (Table 1). Most patients (n = 23) were
victims of road traffic accidents (82.2 %), and the
remaining patients sustained a fall (n = 3) or other in-
jurious mechanisms (n = 2). The GCS at the scene was ≤8
for all patients with the exception of three patients who
had an initial GCS of 9–10 and rapidly deteriorated re-
quiring intubation prior to admission to the hospital. The
Injury Severity Scores (ISS) were recorded to assess the
combined injuries sustained including brain and periph-
eral trauma. Median ISS for this cohort was 36.5 ranging
between 13 and 57, which is indicative of a high incidence
of additional injuries to TBI. Outcome assessed at 6
months post-TBI was generally poor with a median GOSE
of 4. Following dichotomisation, 18 patients had an un-
favourable outcome with GOSE 1–4 (64.3 %), whereas10 patients had a favourable outcome with GOSE 5–8
(35.7 %); 6 patients died (GOSE 1) during the first 6
months from injury.Changes in tryptophan metabolites and increases QUIN in
CSF after TBI
The levels of TRP in CSF showed an apparent increase
between day 0 and 5 after TBI; however, the median
concentrations (average median 4255 nM, 25–75 per-
centile: 2088–7358 nM) were not significantly different
from controls (median: 3000 nM, 25–75 %: 2260–4690
nM) (Fig. 1a). In the TBI cohort, KYN displayed median
levels ranging between 115.1 and 163.6 nM over the
days 0 to 3 and were similar to control with a median of
78.48 nM (25–75 %: 56.21–98.62 nM; Fig. 1b). However,
later in the study at days 4 and 5 post-injury, KYN con-
centrations became significantly elevated of at least
twofold over controls with median values of 188.0 nM
(25–75 %: 105.5–249.3 nM) and 228.0 nM (25–75 %:
173.1–444.1 nM; p < 0.05) on each day, respectively. In
CSF, TBI induced an early and gradual elevation of the
NMDA antagonist KYNA, which became significantly
higher than controls from day 2 onwards (control median:
73.08 nM, 25–75 %: 37.86–105.8 nM; day 2 median: 127.3
nM, 25–75 %: 80.13–237.1 nM, 1.7-fold increase; p < 0.05;
Fig. 1c). After day 2, KYNA reached a plateau that lasted
until day 5 with median concentrations between 127.3 and
143.5 nM.
In contrast to KYNA, the other potent NMDA receptor
agonist, QUIN, increased over control as early as day 1 to
further augment from day 2 to day 4 before showing a
mild decrease on day 5, which was still significantly higher
than control (p < 0.05; Fig. 1d). In more detail, the concen-
tration of QUIN was unchanged at day 0 (median: 21.4
nM, 25–75 %: 12.9–43.5 nM) and began to increase from
day 1 (median: 79.6 nM, 25–75 %: 47.32–127.6 nM)
(Fig. 1d), reaching a peak at day 4 (median: 229.4 nM,
25–75 %: 146.4–438.2 nM), which represented a tenfold
increase from control levels (p < 0.005). Of note, the
concentrations of QUIN in control CSF (median: 3 nM,
25–75 %: 3–34.5 nM) matched the normal CSF levels
reported by others in the literature (<50 nM) (see re-
view [17]).
The median concentration of AA steadily increased
after TBI with an apparent peak of 12.5 nM (25–75 %:
7.4–22.2 nM) detected at day 4, which consisted of an ~2-
fold increase from the control level (Fig. 1e). In comparison,
the downstream product of AA and precursor of QUIN,
3HAA, displayed a 2- to 5-fold increase between days 1
and 4, despite the large variations observed throughout
the study (Fig. 1f ). For both AA and 3HAA, there were
no statistically significant differences to control at any
time point examined.
CSF 3HAA



















































































































































































Fig. 1 Profile of the kynurenine pathway metabolites in the CSF of patients with TBI. The concentration of six tryptophan metabolites was measured in
the CSF of TBI patients consecutively from the day of hospital admission (day 0) to day 5 after injury and compared to the CSF of control individuals. a
Tryptophan (TRP), b kynurenine (KYN), c kynurenic acid (KYNA), d quinolinic acid (QUIN), e anthranilic acid (AA) and f 3-hydroxyanthranilic acid (3HAA).
Data is presented as daily median with 25–75 percentile. Asterisks indicate significant differences (p < 0.05) to control using one-way ANOVA followed
by Dunnett’s multiple comparison as post hoc. TBI patients: n = 25–28 per time point; control group: n = 9–11. Significant increase of KYNA concentration
in CSF were observed between days 2 and 5 when compared to the control level, while QUIN concentration was significantly increased between days 1
and 5 as to the controls
Yan et al. Journal of Neuroinflammation  (2015) 12:110 Page 8 of 17KP activity shifts towards the production of the excitotoxic
metabolite QUIN
KYNA and QUIN are end products of two distinct
branches of the KP and are released at different concen-
trations in both normal and disease conditions [37]. We
then further explored the impact of TBI to drive the KP
towards excitotoxicity and QUIN production, manifested
through disproportional amounts of KYNA and QUIN;
we calculated the ratios of each one of these metabolites
with their common precursor KYN.
Interestingly, we found a significant and protracted in-
crease in the ratio of QUIN and KYN from day 1 to
day 5 post-TBI (Fig. 2a). This striking elevation reached
a maximum of 28.8-fold over control levels on day 4(p < 0.05). In contrast, the ratios of KYNA and KYN
(range of median values from 0.51 to 1.1) as well as the
ratios of 3HAA and AA (range of median values from
0.24 to 1.46) remained unchanged throughout the study
and were not different from controls (median: 0.65)
(Fig. 2b–d). The overproduction of QUIN was also sup-
ported by the ratio of QUIN and its neuroprotectant
counterpart, KYNA, which presented significantly higher
values from day 2 to day 5 after TBI (median: day 2 = 1.3,
day 3 = 0.76, day 4 = 1.97 and day 5 = 1.3) when com-
pared with controls (median: 0.3) (Fig. 2c).
These results demonstrate substantial changes in KP
activity induced by TBI, whereby metabolism of TRP
was shifted towards an enhanced release of neurotoxic
CSF KYNA:KYN







































































































Fig. 2 Ratios of metabolites of the kynurenine pathway indicate a higher production of quinolinic acid. The daily CSF concentrations of each
metabolite were used to calculate the individual ratios depicted as follows: a kynurenic acid (KYNA) versus kynurenine (KYN), b quinolinic acid
(QUIN) versus KYN, c QUIN versus KYNA and d 3-hydroxyanthranilic acid (3HAA) versus anthranilic acid (AA). Data is shown as median with 25–75
percentile. Asterisks indicate significant differences (p < 0.05) to control group using one-way ANOVA followed by Dunnett’s multiple comparison
as post hoc. TBI patients: n = 25 per time point; control group: n = 9. Significant increase in the ratio of QUIN to KYN and QUIN to KYNA when
compared to the control level indicating QUIN production increased after TBI
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with the end products KYNA or AA.
Serum concentrations of tryptophan decrease after TBI
We were also interested to determine how changes in
the production of TRP observed in CSF relate with TRP
levels in the blood. Interestingly, the concentration of
serum TRP was significantly decreased from day 0 to
day 4 following TBI with a reduction ranging between
25 and 50 %, p < 0.05 (Fig. 3). Although the medians of
TRP on day 5 (36.29 μM, 25–75 %: 29.34–44.37 μM) and
day 4 (35.6 μM, 25–75 %: 30.63–43.93 μM) were similar,
the apparent increase of TRP on day 5 was not found to
be statistically different to control levels (p = 0.274), pos-
sibly due to a larger data variance at this time point.
Up regulation of IDO1 mRNA in the injured brain supports
the increase of QUIN in CSF
This section of the study aimed at elucidating the mecha-
nisms leading to the alterations in KP metabolite detected
in the CSF of TBI patients and substantiating the evidence
of KP activation directly on the injured brain. Using post-mortem brain tissue from TBI victims, we examined
changes in the expression level of six enzymes of the
KP, namely IDO1, KYNase, KAT-II, KMO, 3HAO and
QPRTase, which were normalised to a set of three con-
stitutive genes to generate reliable PCR data (see the
‘Materials and methods’ section).
IDO1 is the first enzyme required in the initial step of
the KP to metabolise TRP into KYN. KYNase is needed
for metabolising 3HK into 3HAA prior to the final con-
version of the latter into QUIN. IDO1 mRNA levels
were significantly increased at least fivefold in the De-
layed Death Injured Tissue as compared to the controls
(p < 0.05; Fig. 4a). There were no significant differences
observed on the IDO1 levels between the other groups
(i.e. Acute Death vs control and Delayed Death Normal
Tissue vs control). A similar pattern was also observed
in the KYNase mRNA levels whereby over a sevenfold
increase was detected in the Delayed Death Injured Tissue
over the controls (Fig. 4b, p < 0.05) and no differences be-
tween the other groups. In contrast, mRNA expression of
KAT-II, KMO, 3HAO and QPRTase remained unchanged
in both the acute and delayed death groups (Fig. 4c–f ).























Fig. 3 The concentration of tryptophan in serum is reduced after TBI.
The concentration of tryptophan in serum samples of TBI patients was
measured from the day of hospital admission (day 0) to day 5 after injury
and compared to the control serum. Significant decrease in serum TRP
levels were observed between days 0 and 4; there was no statistical
difference at day 5 to control levels, but median concentration at day 5
(36.29 μM) was similar to day 4 (35.6 μM). Data is shown as daily median
with 25–75 percentile. Asterisks indicate significant differences (p < 0.05)
between TBI and control using one-way ANOVA followed by Dunnett’s
multiple comparison as post hoc. TBI patients: n = 25–28 per time point;
control group: n = 9–11
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in CSF following TBI is supported by the upregulation of
mRNA expression of those enzymes of the KP involved in
the synthesis of QUIN, IDO1 and KYNase.
Expression of active IDO1 protein is increased in the
injured brain
We next seek to determine the localisation of active IDO1
enzyme on post-mortem brain tissue to be related to the
findings of upregulated IDO1 mRNA shown above. Using
an antibody that specifically recognises activated IDO1,
immunohistochemistry revealed a significant increase in
the number of IDO1-positive cells after TBI, which peaked
in acute TBI and gradually declined in the injured and
normal tissue of delayed death patients.
The highest amounts of cells expressing IDO1 were
detected in the brains of patients with acute death after
TBI (19.1 ± 3.1 % of total cells; Fig. 5a(III,IV), Fig. 5b)
compared to control tissues (6.2 ± 0.8 %; p = 0.0286;
Fig. 5a(I,II)). Although the number of IDO1-positive
cells was lower in the Delayed Death Injured Tissue,
they were still significantly elevated (12.1 ± 2.3 %) com-
pared to control (Fig. 5a(V,VI), Fig. 5b). For comparison,
analysis of the brain region of the delayed death that did
not present evident tissue pathology showed no increase
in IDO1 protein expression, having similar numbers of
IDO1-positive cells to control brains (Fig. 5a(VII,VIII),
Fig. 5b). Based on the microscopic evaluation, cells ex-
pressing IDO1 have morphology typical of pyramidalcortical neurons, thus suggesting their potential contri-
bution to the activation of the KP. Together, this im-
munohistochemical data supports the hypothesis that
IDO1 is indeed activated in the injured brain.
QUIN concentrations in CSF correlate with outcomes
scores
Previous studies reported that higher concentrations of
QUIN in CSF correlated with mortality in adult and
paediatric TBI patients [28, 29]. We, therefore, investi-
gated the relationship of QUIN with outcome scores at
6 months post-TBI. We performed a Pearson correlation
of coefficient between the GOSE scores and maximal
CSF concentration of QUIN between days 1 and 5 after
TBI. A significant inverse correlation was observed be-
tween QUIN and GOSE with r = −0.46 and p < 0.02
(Fig. 6a). This correlation indicates a potential prognostic
value for QUIN, whereby patients with higher QUIN pro-
duction in the acute phase after injury have poor recovery
at 6 months post-injury. Furthermore, we dichotomised
TBI patients according to favourable (GOSE 5–8) and
unfavourable outcome (GOSE 1–4) scores. Patients
with unfavourable outcome had a close to significant
higher concentration of QUIN (median: 0.28 μM, 25–75 %:
0.20–0.48 μM) than patients with favourable outcome (me-
dian: 0.17 μM, 25–75 %: 0.08–0.26 μM) (p = 0.056; Fig. 6b).
Discussion
Clinical studies have shown that secondary injury processes
induced by TBI generate ongoing disease-like charac-
teristics that cause progressive brain damage, delay
physical recovery and contribute to the onset of mental
illness. Therefore, early treatment aimed to reduce acute
pathological sequel is the major focus in the development
of therapeutic strategies in TBI patients. It is well estab-
lished that excitotoxicity, neuroinflammation and oxidative
stress are pivotal pathways of secondary brain damage
following TBI [38]. Studies of neurodegenerative dis-
eases and infection of the nervous system have shown
that TRP metabolism participates in the regulation of
immune activation, generation of oxidative radicals and
production of excitotoxic substances [17]. Despite ro-
bust evidence showing that the KP plays an important
role in neuropathology, this pathway has only been
sporadically examined in the context of TBI. This gap
spurred the current investigation aimed at measuring a
number of metabolites of the KP in live, severely injured
TBI patients’ CSF and understanding how these metabo-
lites relate to the expression of critical enzymes of the KP
in post-mortem brain tissues of TBI victims. Our data
demonstrates that the KP is profoundly activated after
brain trauma by showing increased concentration of a
number of TRP metabolites in CSF, including KYN,






















































































































































































































































Fig. 4 qPCR analysis of enzymes of the kynurenine pathway in brains of TBI victims demonstrates enhanced IDO1 and KYNase expression. Gene
expression of six enzymes of the kynurenine pathway was determined by qPCR in four groups of post-mortem brains obtained from the temporal
cortex after TBI and uninjured control individuals (n = 10). Groups comprise the following: TBI patients with acute death (survived <17 min after
injury, n = 9), TBI patients with delayed death (survival between 6 and 122 h, n = 7) with tissue collected from brain regions having evident tissue
pathology (Delay Death Injured Tissue) and brain regions without macroscopic damage obtained from the contralateral uninjured side (Delay
Death Normal Tissue) (n = 7). a Indoleamine-pyrrole 2,3-dioxygenase (IDO1), b. kynurenase (KYNase), c kynurenine amino transferase-II (KAT-II),
d kynurenine 3-monooxygenase (KMO), e 3-hydroxyanthranilic acid oxygenase (3HAO) and f quinolinic acid phosphoribosyl transferase (QPRTase).
Asterisks indicate significant differences (p < 0.05) between TBI and control groups using one-way ANOVA followed by Dunnett’s multiple comparison
as post hoc. Data shown as median with 25–75 percentile. IDO1 and KYNase were significantly increased in the Delay Death Injured Tissue group as to
the control samples
Yan et al. Journal of Neuroinflammation  (2015) 12:110 Page 11 of 17metabolite QUIN likely arises from the activation and
overexpression of the enzyme IDO1 subsequently driv-
ing the pathway into the production of intermediate
metabolites 3HK (passive intermediate) and 3HAA via
the activation of KYNase.We need to distinguish between IDO1 enzyme activa-
tion detected by immunohistochemistry and upregulation
of IDO1 mRNA measured by PCR to explain the different
timing of the changes observed. IDO1 is stored in a

















































Fig. 5 Immunohistochemistry of post-mortem brains reveals increased IDO1 acutely after TBI. a IDO1 immunohistochemistry was performed on
post-mortem brains as described in the ‘Materials and methods’ section. IDO1 is found increasingly expressed in Acute Death and Delayed Death
Injured Tissue samples compared to the control. Top panels (i, iii, v, vii) indicate ×200 magnification; bottom panels (ii, iv, vi, viii) indicate ×600
magnification. Figures represent IDO1 immunohistochemistry of the cortex of the uninjured control group (i and ii), acute death (<17 min after
injury; Acute Death) (iii and iv), tissue obtained from injured cortex of TBI patients with delayed death (survival between 6 and 122 h; Delay Death
Injured Tissue) (v and vi) and tissue collected from regions without macroscopic damage of the contralateral uninjured side (Delay Death Normal
Tissue) (vii and viii). Rectangular boxes in the ×200 panels indicate the magnified regions of ×600. Brain sections were counterstained with haematoxylin.
b IDO immunohistochemistry staining was semi-quantitatively assessed in post-mortem brain samples and presented as the percentage of positively
stained cells relative to the total number of cells per field. Statistical differences were calculated as described in the Materials and methods
section, *p ≤ 0.05. Data are mean ± SEM. Significant increase in the number of IDO1-positive cells was observed in Acute Death and Delayed
Death Injured Tissue as compared to the controls; similar levels of IDO1-positive cells were between Control and Delayed Death Normal Tissue groups
Yan et al. Journal of Neuroinflammation  (2015) 12:110 Page 12 of 17phosphorylation occurring within a few minutes from
stimulation [39, 40]. This activation process makes IDO1
recognisable to the mAb used in immunohistochemistry
of post-mortem early-injured brains presented in Fig. 5.Unfortunately, there is no commercially available antibody
for the dephosphorylated/inactive form of IDO1 to allow
for its detection in situ. Moreover, activated IDO1 has the
capacity of auto-amplification, a fact that may explain the
CSF QUIN vs GOSE































Fig. 6 The concentration of QUIN in CSF is inversely correlated with GOSE scores and is significantly more elevated in patients with unfavourable
outcome. a Correlative analysis was undertaken using maximal concentration of QUIN in CSF of each patient between day 0 (admission to hospital)
and day 5 post-TBI and the GOSE scores assessed at 6 months after TBI. A significant negative correlation (p < 0.05) was observed between QUIN and
GOSE scores with r = −0.46 (n = 28). b TBI patients were grouped into favourable (GOSE 5–8, n = 11) and unfavourable outcome (GOSE 1–4, n = 15)
and their maximal QUIN concentration compared between the groups. Patients with unfavourable outcome showed a close to significant (p = 0.056)
higher concentration of QUIN in CSF compared to patients with favourable outcome
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of delayed survival times between 6 and 122 h post-TBI
[39] (Fig. 4a).
In regard to the immunohistochemistry experiments,
our data has to be taken with caution given the limited
number of tissues stained and the variety of brain re-
gions analysed. Importantly, however, these experiments
confirm that active IDO1 protein is indeed present in
the brain early after trauma, corroborating the hypothesis
that IDO1 activation is actually increased within a few
minutes after TBI (Fig. 5a,b). We are aware that these
results warrant further investigations to explore the
mechanisms and profiles of IDO1 activation after TBI
to allow for a comprehensive quantification and under-
standing of its role in the ultimate activation of the KP.
Collectively, the analysis of the KP metabolite in CSF
and the expression of the KP enzymes in post-mortem
brain tissue suggests that the QUIN production is increased
via the activation of the minor branch of the KP, beginning
from the metabolism of KYN to AA, the production of
3HAA and finally the accumulation of QUIN. This hy-
pothesis is also supported by the gradual increase in
the concentration of AA in CSF (Fig. 1e), which, although
not significant, displays a pattern strikingly similar to the
pattern observed for QUIN production (Fig. 1d).
In addition, we report of an inverse correlation be-
tween elevated QUIN in CSF and the adverse long-term
outcome, corroborating both a detrimental role of QUIN
in the pathophysiology of secondary brain damage as
well as the potential therapeutic implications of targeting
QUIN production to reduce morbidity in this patient
population.
The KP represents the major metabolic cascade of
TRP metabolism, which degrades up to 90 % of available
amino acid. The KP is dramatically enhanced in diseaseconditions that particularly involve the activation of the
immune system. We and others have focused much of
our research efforts in characterising the inflammatory
response resulting from TBI, via clinical and experimental
investigations (reviews [41, 42]).
During an inflammatory response, the release of cyto-
kines, in particular IFN-γ, by activated monocytes and
leukocytes increases the degradation of TRP via the KP
[43]. This likely occurs through the ability of IFN-γ to
activate the upstream enzyme IDO1 of the KP, which
may become highly processed to release bioproducts
such as QUIN, known to promoting excitotoxicity. We
have previously shown that IFN-γ is rapidly upregulated
in the CSF of severe TBI patients. In addition, using the
same brain homogenates analysed in this study, we
demonstrated that IFN-γ was already found enhanced
in early death brains with even greater concentrations
in the delayed death brains by a sixfold increase from
controls [36, 44]. In fact, among the eight cytokines
analysed, IFN-γ was the third highest cytokine following
IL-6 and IL-8 [36].
We cannot exclude, however, the contribution of other
factors in the activation/upregulation of IDO1. In fact,
in vitro studies on cultured microglia have demonstrated
IFN-γ-independent activation of IDO1 by TNF-α and
IL-1β [45]. This point is pertinent to our study as we
have previously shown a fourfold elevation of TNF-α at
protein/mRNA levels in the same post-mortem brains
harvested within 17 min post-injury while a nonsignifi-
cant increase of IL-1β mRNA was observed early (17
min) which was followed by a substantial and significant
upregulation of over fivefold in the delayed group dying
beyond 6 h from TBI [36]. It is conceivable that com-
bined increase of these cytokines early after TBI results
in subsequent and significant induction of IDO1 mRNA
Yan et al. Journal of Neuroinflammation  (2015) 12:110 Page 14 of 17that was observed in the injured brain of delayed death
patients (Fig. 4a).
In our study, the levels of TRP in CSF remained within
a normal range whereas the blood concentrations were
found below physiological values during almost the en-
tire acute phase post-TBI. It is important to note that in
healthy conditions the concentration of TRP in serum is
tenfold higher than the CSF level. Although serum TRP
decreased up to 50 % after injury, its blood levels were still
higher compared to CSF. The striking difference between
these two compartments may allow sufficient amounts of
TRP to be transported to the brain or CSF via the brain/
CSF barrier to maintaining a constant CSF concentration,
which may explain the lack of changes of TRP in CSF.
Decreased concentrations of TRP in serum were reported
previously in patients with infectious and neurodegenera-
tive diseases and cancers. The authors speculated that this
phenomenon is caused by an enhancement in peripheral
IDO1/TDO enzyme activity [46]. Our observation of a sig-
nificant decrease of TRP in serum after TBI confirms the
findings reported by others in multiple trauma patients
showing that blood TRP was significantly attenuated [46].
Although cytokines can strongly affect the KP, it has
been demonstrated that TRP itself possesses important
immune-regulatory properties. TRP depletion suppresses
the proliferation of mononuclear cells [5], decreases im-
mune cell activation [6, 47] and inhibits parasitic growth
[48]. Therefore, a low concentration of serum TRP may
provide some beneficial effects in the early stage after
severe brain injury by reducing acute inflammatory re-
sponses. However, with the current setting, our study is
unable elucidate the underlining mechanisms leading to
the reduction of TRP in blood, a question which warrants
further investigations.
Analysis of gene expression of the KP enzymes indicated
that KP is strongly activated after TBI. The enzyme KAT
has four isoforms, which are responsible for the synthesis
of the neuroprotectant KYNA from its precursor KYN
[49]. In this study, we have only examined KAT-II, one of
the major KATs involved in both normal and disease
conditions, which is considered as a promising target for
pharmaceutical intervention. The expression of KAT-II in
post-mortem brain did not vary between the three groups
of TBI patients, Acute Death, Delayed Death Injured Tissue
and Delayed Death Normal Tissue relative to control
tissues. The unchanged expression levels of KAT-II ob-
served in these brains are consistent with the unaltered
concentration of its bioproduct KYNA in CSF between
days 0, 1 and 2 and controls (Fig. 1c). It is important to
consider that the average survival time of the delayed
group is 40 h; thus, the tissue sample collected from
these victims occurred well before the observed increase
of KYNA in CSF, which was only found to be significant at
3 days post-injury. Here, we cannot adequately explain themechanisms leading to enhanced KYNA and whether this
is due to the increase of KAT expression/activation or as a
result of an elevated concentration of the precursor KYN.
However, we have to bear in mind that mRNA expression
levels do not reflect changes in enzyme activation, thus
posing a limitation in this study, solely based on qPCR.
Previous work by Han et al. has shown that the Km of
KAT-II is 1.7 ± 0.5 mM [50], a concentration that greatly
exceeds the concentration of KYN in the CSF samples we
found in the control and TBI cases (mean 0.08 ± 0.01 μM
and 0.21 ± 0.02 μM, respectively). Therefore, we cannot
state without doubt that the marked increase in the KYNA
on days 3, 4 and 5 is attributed to the elevation of KYN
following injury.
KMO is the key enzyme converting KYN into 3HK
and subsequently into QUIN. This step of the KP has
been suggested to be the main pathway for QUIN pro-
duction. Inhibition of KMO was effectively ameliorating
QUIN-mediated neurodegeneration in rodent [51]. How-
ever, in our study, KMO did not change significantly after
TBI with median levels remaining similar among the four
groups examined (Fig. 4d).
Newly emerged evidence demonstrated the important
roles of 3HAA and AA in both brain and periphery in
normal and disease conditions (see review by Darlington
et al. 2010 [52]). Studies on osteoporosis [53], Huntington’s
disease [54, 55], stroke [32] and depression [56] have shown
a simultaneous increase in AA and reduction in 3HAA in
blood. In the brain, AA is an effective inhibitor of 3HAO
[57]; therefore, the increase in AA in neurodegenerative
diseases may provide some degree of inhibition of 3HAO
that is required for the synthesis of the neurotoxin QUIN.
Our study demonstrated that the ratios of 3HAA and AA
are higher in the early days after TBI and gradually de-
creased, suggesting an overproduction in AA compared to
3HAA over time.
Despite the lack of changes in those metabolites up-
stream to QUIN synthesis (3HAA, 3HK not measured)
and despite the elevation of KYNA—a metabolite gener-
ated via a separate branch from the one responsible for
QUIN production—evidence for enhanced activation of
the branch of the KP pathway leading to increased
QUIN reported in this study is based on the following
data: (1) prolonged elevation of QUIN in CSF of TBI pa-
tients, (2) increased QUIN:KYN and QUIN:KYNA ratios
from CSF measurements of these metabolites, (3) in-
creased IDO1 and KYNase mRNA expression in human
brains and (4) enhanced acute expression of IDO1 pro-
tein on neurons in the injured brain region but not in
tissue areas of normal appearance.
QUIN exerts its neurotoxic activity by interacting with
a subgroup of NMDA receptors leading to a widespread
destruction of neuronal terminals and sparing fibres [58].
In cultured cortico-striatal neurons, prolonged exposure
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totoxic damage [59]. Further, in vivo studies using intras-
triatal injection of QUIN showed tissue lesions similarly
located in the basal nuclei as occurring in Huntington’s
disease patients [60]. Another recent in vivo study also
demonstrated that brain regions, i.e. cerebellar cortex,
hippocampus and cerebellum, have different susceptibility
to QUIN-induced oxidative stress [61].
Our recent studies in NSC-34, a mouse motor neuron
cell line, demonstrated that 2 μM QUIN is highly toxic
and that uptake of QUIN by NSC-34 cells occurs as
early as 30 min after exposure to QUIN [62]. QUIN
neurotoxicity is mediated by both direct and indirect
mechanisms. It has been reported that QUIN can directly
increase free radical generations once entering the cells
[63–65]. Free radical production following hypoxia-ische-
mia in association with inflammation plays a prominent
role in the ultimate death of cells. Free radicals can cause
cellular injury via several mechanisms, including mem-
brane lipid peroxidation, oxidative damage of proteins
and DNA and RNA fragmentation [66]. QUIN has been
shown to chelate Fe2+ to form a QUIN-Fe2+ complex,
which results in the production of the most toxic hydroxyl
radical via the Fenton reaction [67]. Accumulation of
QUIN in neurons has been shown in Alzheimer’s disease
[9], motor neurons in ALS [68] and neuronal cell line [62].
Collectively, these multiple biochemical pathways in which
QUIN may be involved have been demonstrated to be
contributing elements within the complex mechanisms of
secondary brain damage arising from TBI.
Studies have shown significant associations between
QUIN concentration and severity of the infectious dis-
eases of the nervous system. Concentration of CSF
QUIN is elevated 3.5-fold in the early stage of im-
munodeficiency syndrome (AIDS) patients [18], while it
increased over 20-fold in patients at the late stage of the
disease [18]. A higher level of CSF QUIN in individuals
with HIV infection was positively correlated with more
severe motor deficits [69]. In the context of outcome
following TBI, these observations are consistent with
the finding of our study, whereby we detected a significant
negative correlation between patients’ GOSE scores and
QUIN concentrations in CSF, including the evidence of
higher QUIN in patients with unfavourable when com-
pared to those with favourable outcomes. This suggests a
critical role of QUIN as a potential biomarker for the early
prediction of long-term outcome following TBI.
Conclusion
Highly neuroactive products of TRP metabolism have
received considerable attention in the last two decades.
Numerous studies have demonstrated the importance of
TRP and its metabolites in both normal physiology and
disease conditions such as neuroinflammatory, infectiousand neurodegenerative diseases. However, limited reports
have examined changes and roles of TRP metabolism in
TBI. This study is the first to investigate longitudinal
changes in key metabolites of the KP in patients with se-
vere TBI including investigations in brain gene expression
of key regulatory enzymes of the KP in individuals who
died due to TBI. We have obtained novel and convincing
data of enhanced KYNase expression occurring in the
acute phase following TBI. These results indicate that TBI
may selectively activate the branch of the KP leading to
increased QUIN production in the injured brain. This
novel finding supports the concept that blocking the
activity of KYNase (with existing compounds such as
oestrone sulphate or nicotinylalanine) may become an
effective therapeutic strategy in attenuating QUIN produc-
tion and its driven excitotoxicity, thus diminishing the det-
rimental consequences of secondary brain damage.
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